# Efficacy and Safety Study of MP-513 in Combination With Sulfonylurea in Patients With Type 2 Diabetes

> **NCT00974090** · PHASE3 · COMPLETED · sponsor: **Tanabe Pharma Corporation** · enrollment: 194 (actual)

## Conditions studied

- Type 2 Diabetes Mellitus

## Interventions

- **DRUG:** Placebo / Teneli (Teneligliptin) + SU (Sulfonylurea)
- **DRUG:** Teneli / Teneli + SU

## Key facts

- **NCT ID:** NCT00974090
- **Lead sponsor:** Tanabe Pharma Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-09
- **Primary completion:** 2011-03
- **Final completion:** 2011-03
- **Target enrollment:** 194 (ACTUAL)
- **Last updated:** 2026-01-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00974090

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00974090, "Efficacy and Safety Study of MP-513 in Combination With Sulfonylurea in Patients With Type 2 Diabetes". Retrieved via AI Analytics 2026-08-01 from https://api.ai-analytics.org/clinical/NCT00974090. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*